ArticleFuture oncology (London, England)2026

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or

Alison M Schram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.